Interestingly, the genomic alterations of BLBC, including BRCA1 inactivation, RB1 loss, cyclin E1 amplification, high expression of AKT3, MYC amplification/high expression, a high frequency of TP53 mutations, and high pathway activity of the HIF1-a/ARNT, MYC, and FOXM1 regulatory hubs, resemble those of serous ovarian carcinoma, indicating potential similarities between the two cancer types in regards to pathogenesis and therapeutic opportunities [7]. This evidence concerns the gene MYC and ovarian serous carcinoma.